The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study
Ezekowitz, Justin A., Becher, Harald, Belenkie, Israel, Clark, Alexander M., Duff, Henry J., Fredrich, Matthias G., Haykowsky, Mark J., Howlett, Jonathan G., Kassiri, Zamaneh, Kaul, Padma, Kim, Daniel H., Knudtson, Merril L., Light, Peter E., Lopaschuk, Gary D., McAlister, Finlay A., Noga, Michelle L., Oudit, Gavin Y., Paterson, D. Ian, Quan, Hude, ... Dyck, Jason R. B.. (2014). The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovascular Disorders. 14(91), pp. 1 - 9. https://doi.org/10.1186/1471-2261-14-91
|Authors||Ezekowitz, Justin A., Becher, Harald, Belenkie, Israel, Clark, Alexander M., Duff, Henry J., Fredrich, Matthias G., Haykowsky, Mark J., Howlett, Jonathan G., Kassiri, Zamaneh, Kaul, Padma, Kim, Daniel H., Knudtson, Merril L., Light, Peter E., Lopaschuk, Gary D., McAlister, Finlay A., Noga, Michelle L., Oudit, Gavin Y., Paterson, D. Ian, Quan, Hude, Schulz, Richard, Thompson, Richard B., Weeks, Sarah G., Anderson, Todd J. and Dyck, Jason R. B.|
Background Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs annually and the global burden is expected to double in the next 1–2 decades. The current one-year mortality rate after diagnosis of heart failure remains high at >25%. Consequently, new therapeutic strategies need to be developed for this debilitating condition.
Methods/Design The objective of the Alberta HEART program (http://albertaheartresearch.ca) is to develop novel diagnostic, therapeutic and prognostic approaches to patients with heart failure with preserved ejection fraction. We hypothesize that novel imaging techniques and biomarkers will aid in describing heart failure with preserved ejection fraction. Furthermore, the development of new diagnostic criteria will allow us to: 1) better define risk factors associated with heart failure with preserved ejection fraction; 2) elucidate clinical, cellular and molecular mechanisms involved with the development and progression of heart failure with preserved ejection fraction; 3) design and test new therapeutic strategies for patients with heart failure with preserved ejection fraction. Additionally, Alberta HEART provides training and education for enhancing translational medicine, knowledge translation and clinical practice in heart failure. This is a prospective observational cohort study of patients with, or at risk for, heart failure. Patients will have sequential testing including quality of life and clinical outcomes over 12 months. After that time, study participants will be passively followed via linkage to external administrative databases. Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant. Patients will be followed for a total of 5 years.
Discussion Alberta HEART has the primary objective to define new diagnostic criteria for patients with heart failure with preserved ejection fraction. New criteria will allow for targeted therapies, diagnostic tests and further understanding of the patients, both at-risk for and with heart failure.
|Keywords||Heart failure; Preserved ejection fraction; Heart failure risk factors; Heart failure diagnosis|
|Journal||BMC Cardiovascular Disorders|
|Journal citation||14 (91), pp. 1 - 9|
|Digital Object Identifier (DOI)||https://doi.org/10.1186/1471-2261-14-91|
|Open access||Open access|
|Page range||1 - 9|
|Research Group||Mary MacKillop Institute for Health Research|
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ([http://creativecommons.org/licenses/by/4.0] http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
0views this month
0downloads this month